New Hope For Serious Infections

Jefferies 2016 Healthcare ConferenceJune 7-10, 2016Grand Hyatt, New York City

Forward-Looking Statements

These slides and the accompanying oral presentation (the “Presentation”) contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effectiveness, safety, long-acting nature, anticipated human dosing, potential to treat infections and other attributes of CD101 IV and CD101 topical, as well as the incidence of fungal infections and the effectiveness and treatment protocols for competitive therapies. Statements regarding the intended design of current and future Cloudbreak compounds are forward-looking. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-K most recently filed with the United States Securities and Exchange Commission (SEC), under the heading “Risk Factors.” All forward-looking statements contained in the Presentation speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Cidara April 2015: two preclinical platforms

Volk

er B

rink

man

n, W

ikim

edia

.org

CD101 IV: Pre-clinical Cloudbreak™: Immunotherapy

1 year post-IPO: substantial progress

CD101 IV for candidemia, Phase 2

CD101 topical for VVC, Phase 2

CD101 prophylaxis & other

CD101 IV for candidemia, Phase 2CD101 topical for VVC, Phase 2CD101 prophylaxis & other

In-vivo proof of concept, antifungal

In-vivo proof of concept, antibacterial

Expanding to antiviral

In-vivo proof of concept, antifungalIn-vivo proof of concept, antibacterialExpanding to antiviral

Volk

er B

rink

man

n, W

ikim

edia

.org

Cloudbreak™CD101

2015 2016

FDA fast-track & QIDP for CD101 IVMay, 2015

Submits IND to FDA for CD101 IVJun, 2015

Positive Phase 1 SAD/MAD CD101 IVNov 2015/ Jan 2016

IPO: $77MApr, 2015

Solid execution beyond plan

CloudbreakDevelopmentcandidate

Orphan drug statusCD101 IV Feb, 2016

Phase 2 startCD101 IV CD101 topical

FDA fast-track & QIDP for CD101 topicalMay, 2016

U.S. 12-Week Mortality per Annum by Species

Fungal infections: high mortality

Rare Fungi

Cryptococcus

Aspergillus

Candida

2,500

4,500

22,500

67,500

97,000deaths per year

Echinocandins: first line therapy for candidemia

DRUG PROFILE• First line treatment for Candida

• Safe and well tolerated

• Superior to azoles

BUT CONSTRAINED• Once daily IV

• Low exposure – suboptimal dosing

• Growing resistance

USD Billions

4.20.5

1.1

2.6

Polyenes

Echinocandins

Azoles

Today

CD101 opportunity: expand echinocandin market

ACCESS ENTIRE>$4 BILLION MARKET

• Inpatient & outpatient

• Treatment & prophylaxis

• Penetrate azole class

• Expand indications

4.20.5

1.1

2.6

Polyenes

Echinocandins

Azoles

~2x

Today

FutureIllustrative

USD Billions

Cubicin established precedent as IV outpatient

“From hospital to home”

Outpatient sales (2015)Share of outpatient marketInitial projection inpatient

~$720M:20%:

$240M:

Potential value*CD101 potential shareEchinocandin current share

~$625M:~15%:

4%:

CUBICIN Outpatient CD101 Outpatient

Assumptions: 14 days OPAT: Micafungin cost per day (WAC) - $187, Cost of PICC placement - $1,024, Per diem OPAT costs - $219*Assumes CD101 captures outpatient share = 80% current echinocandin inpatient share

“From hospital to home”

CD101 – a differentiated echinocandin

ICAAC 2015

• Prolongs PK

• Allows high exposures

• Eliminates toxic degradation products

• Enables multiple formulations

once weekly dosing

treats less susceptible pathogens

improved safety & dose range

systemic and topical

Structural modification yields improved chemical & biological properties

OH

N

NH

OHHNO

O

CH3

OH

HN

NH

HO

N

HO

HO

H3C

O

HO

OH

O

O

O

O

OHN

H3C

O

N+

O-

O

Biafungin (CD101 Acetate)

ON+

10

Log 1

0CFU

/Kid

neys

CFU in kidneys of mice 24 hours after infection with C. albicans and treatment with anidulafungin or CD101

DOSE

Cohort 3

1.5 mg/kg

Cohort 2

0.5 mg/kg

CD101 IV

1

2

3

4

5

0

Untreated Control

0.0 mg/kg

24 hours

CD101 – Superior efficacy vs anidulafungin

Anidulafungin

CONFIDENTIAL

11

CD101 IV: streamlined development plan

PK and safety in healthy volunteers

Double-blind vs. echinocandin in candidemia

Phase I Phase 2

Non-inferiority vs. echinocandinin candidemia

IND I II III

Phase 3

+invasive candidiasis

Phase 1 Single Ascending Dose (SAD) Study Design

1 7 14 21DAYS

50mg

100mg

200mg

400mg

Each Dosing Group:

• 6 CD101 subjects• 2 placebo subjects• Dosed on day 11 7 14 21

1 7 14 21

1 7 14 21

Phase 1 SAD study: safe and well tolerated

• No serious or severe AEs

• No dose response in AEs

• No withdrawals due to AEs

• No clinically significant:• Lab abnormalities

• ECG

• Vital signs

DOSE 50 mg 100mg 200 mg 400 mg Placebo

Subjects w/ AEs 3 of 6 0 of 6 3 of 6 1 of 6 5 of 8

Adverse Events by Dose

0

5

10

15

20

25

0 1 2 3 4 5 6 7

Mea

n Pl

asm

a Co

nc(µ

g/m

L)

Days

AUC ~2.5x greaterAUC ~1.6x higher

Once weekly high exposure dosing

CD101 IV Phase I PK

Cmax 3x higher

Anidulafungin100mg x 7

400mg x 1

200mg x 1

Phase 1 Multiple Ascending Dose (MAD) Design

100mg

200mg

400mg

Each Dosing Group:

• 6 CD101 subjects• 2 placebo subjects• Dosed on days 1 and 8

1 8Dosing day

1 8

1 8 15

1 7 14 21DAYS

1 7 14 21

1 7 14 21

Phase 1 MAD study: safe and well tolerated

• No serious or severe AEs

• No withdrawals due to AEs

• No elevation of LFTs (AST, ALT, Alk Phos, Bili) in any CD101 subject • Mild transient infusion reactions

associated with 400mg dose (primarily with the third dose)

DOSE 100 mg 200mg 400 mg* Placebo

Subjects w/ AEs 3 of 6 2 of 6 4 of 6 2 of 6

Adverse Events by Dose

*Dosed weekly for 3 weeks

CD101 IV Phase 1 Summary

CD101 IV is safe and well-tolerated up to 400mg

Adverse events were similar between placebo and CD101

PK was dose-proportional and supports once weekly dosing

Phase 2: first of two studies for approval

CD101 IV400/400/(400)mg

1 8Dosing day 15 (optional)5

Mycological response

14

Mycological & Clinical response

1o END POINT

28

Mycological & Clinical response

35n=30

CD101 IV400/200/(200)mg

1 8Dosing day 15 (optional)5 14 28 35n=30

1 7 14 21 28

1 7 14 21 28

Caspofungin IV70/50/(50)mg

1 7 14 21 28

5 1428 35n=30

70mg 50mg daily→

15 (optional)1 2

VVC/RVVC has widespread impact

OTC Topical

75% have VVC in their lifetimeUS: 4-5M suffer RVVC

Rx Topical or Oral

US: 4.4M visits per year

Existing therapies have significant limitations

30-40% women fail acute treatment

50% relapse in RVVC

No coverage of non-albicans Candida

Increased risk of miscarriage (flucon)

CDC guidelines recommend only using topical antifungals to treat pregnant women with VVC, including for longer periods than usual if these infections persist or recur

CONFIDENTIAL

21

4

3

2

1

0

5

CD101 Topical eradicates infection in VVC

CONFIDENTIAL

22

D5 D7 D9 D12D1 D5 D7 D9 D12 D5 D7 D9 D12

6Vulvovaginal Candidiasis (VVC) in Rats

InfectTreatCFU

Log 1

0CF

U/m

L la

vage

Topical

Novel Echinocandin CD101 Gel Formulation is Highly Effective in Eradicating Candida albicans in a Rat Model of VVC, L. Miesel, et al.

ICAAC Poster: New Anti-Fungal AgentsSaturday, Sept 19

No Treatment Monistattm CD 101 3% Gel

Day 0 Days 2,3,4Days 5,7,9,12

LOD 0.7

Phase 2 VVC Study Design

DAYS

CD101 3% Gel

CD101 6% Ointment

Fluconazole 150mg

1 2Dosing day

1

1

1 7 14 21 28

1 7 14 21 28

1 7 14 21 28

Efficacy 7 14 28n=50

n=50

n=25

Objectives Safety/tolerability of CD101 Gel/Ointment Efficacy of CD101 Gel vs. CD101 Ointment vs. Fluconazole on Days 7, 14, 28

Mycological & Clinical response at days 7, 14 & 28

CD101 Topical development plan

Dose-ranging safety & efficacy in VVC patients

Phase 2 Pivotal Study 1

Superiority in acute VVC

IND I II III

Pivotal Study 2

Superiority in RVVC

Cloudbreak: a transformational technology

Physically connects the immune system with the pathogen

Vaccine

Primes the immune system

Therapeutic

Targets the pathogen

The strengths of both systems

Cloudbreak™

Cloudbreak™ concept and compound design

Microbe

EFFECTOR MOIETYTARGETING MOIETY

TM EM

MICROBE IMMUNE CELL

Cell

Ex-vivo experimental design

Actual microfluidics chamberMicrofluidic Schematic

NeutrophilInput Well

ConidiaLoading

Ex-vivo proof of concept

No drug 1 nM Cloudbreak (1/70th MEC)

Bifunctional Small Molecule Immunotherapy. C-001 and C-016 Attract Neutrophils (PMNs) to Inhibit Aspergillus fumigatus(Af) Growth in Microfluidic Chambers, D. Irimia, et al.

ICAAC Poster: New Anti-Fungal AgentsSaturday, Sept 19

Cloudbreak™ antibacterial in-vivo POC

No treatment (vehicle) + antibody

Cloudbreak™ treatment - antibody

N=20 per cohort

Cloudbreak™ treatment + antibody

0 20 40 60 80 100

% Survival

MDR E. coli model: carbapenemr, quinoloner, aminoglycosider

Upcoming Milestones

Program Next Milestone Expected Timing

CD101 IV Phase 2 Start 1H 2016

CD101 Topical Phase 2 start Mid 2016

Cloudbreak Platform Development candidate 2016

New Hope For Serious Infections

Jefferies 2016 Healthcare ConferenceJune 7-10, 2016Grand Hyatt, New York City